Bile Duct Neoplasm
NCI Definition: A benign or malignant neoplasm that affects the intrahepatic or extrahepatic bile ducts. Representative examples of benign neoplasms include bile duct adenoma and extrahepatic bile duct lipoma. Representative examples of malignant neoplasms include intrahepatic and extrahepatic cholangiocarcinoma. 
Bile duct neoplasms most frequently harbor alterations in TP53, KRAS, IDH1, ARID1A, and CDKN2A .
TP53 Mutation, KRAS Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, and KRAS Exon 2 Mutation are the most common alterations in bile duct neoplasm .
There is 1 clinical trial for bile duct neoplasm, of which 1 is open and 0 are completed or closed. Of the trial that contains bile duct neoplasm as an inclusion criterion, 1 is phase 2 (1 open).
Nilotinib and paclitaxel are the most common interventions in bile duct neoplasm clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.